ADARx Pharmaceuticals’ IPO debuted with heavy retail and institutional demand, following an upsized offering and a private placement supported by partner AbbVie. The gene-silencing biotech priced the deal at the top of its range, raising about $446 million gross and positioning the company for continued development of onvuzosiran in hereditary angioedema. The listing comes amid strong appetite for RNA therapeutics, with investors focusing on late-stage clinical pathways and partnerships that can de-risk manufacturing, target selection, and commercialization. The ADARx debut also reinforces how capital markets are rewarding platform operators with clear clinical milestones and identifiable revenue and partnering strategies.